Systemic manifestations of inflammatory bowel diseases

Cover Page

Cite item

Full Text

Abstract

The article is devoted to the current data regarding the pathogenesis, classification and frequency of extraintestinal manifestations (EIMs) in inflammatory bowel diseases. We discuss two distinct theories of EIMs pathogenesis. First, EIMs arise from an extension of antigen-specific immune responses from the intestine to non-intestinal sites. Second, EIMs are independent inflammatory events initiated or perpetuated by the presence of IBD or by shared genetic or environmental risk factors in the host. These mechanisms are not mutually exclusive and may contribute to varying degrees in different EIMs. Early diagnosis of EIMs contributes to prevention disability and enhancement of quality of life of IBD patients. It is concluded that treatment of extraintestinal manifestations should be carried out taking into account the course of the IBD and the multidisciplinary approach, which requires close cooperation of doctors of various specialties. Assessment of prognostic markers and predictors for EIM in IBD will be part of a future investigation.

About the authors

A. I. Parfenov

Loginov Moscow Clinical Scientific Practical Center

Author for correspondence.
Email: asfold@mail.ru

д.м.н., проф., зав. отд. патологии кишечника

Russian Federation, Moscow

A. V. Kagramanova

Loginov Moscow Clinical Scientific Practical Center

Email: asfold@mail.ru
Russian Federation, Moscow

O. V. Knyazev

Loginov Moscow Clinical Scientific Practical Center

Email: asfold@mail.ru

д.м.н., зав. отделением воспалительных заболеваний кишечника

Russian Federation, Moscow

References

  1. Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohn’s Colitis. 2019 Apr 26;13(5):541-54. doi: 10.1093/ecco-jcc/jjy191
  2. Парфенов А.И. Энтерология: руководство для врачей. 2-е изд., перераб. и доп. М.: Медицинское информационное агентство, 2009. 880 с. [Parfenov AI. Enterology: Doctor’s Guidelance. Moscow: Medicinskoe informacionnoe agentstvo, 2009. 880 p.) (In Russ.)].
  3. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912-22. doi: 10.1016/s0016-5085(98)70310-5
  4. Biancone L, Mandal A, Yang H, et al. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology. 1995;109:3-12. doi: 10.1016/0016-5085(95)90263-5
  5. Van Sommeren S, Janse M, Karjalainen J, et al. Extraintestinal manifestations and complications in inflammatory bowel disease: From shared genetics to shared biological pathways. Inflamm Bowel Dis. 2014;20:987-94. doi: 10.1097/MIB.0000000000000032
  6. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-36. doi: 10.3748/wjg.v11.i46.7227
  7. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:307-27. doi: 10.1016/s0889-8553(01)00019-x
  8. Taleban S, Li D, Targan SR, et al. Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits. J Crohn’s Colitis. 2016;10:43-9. doi: 10.1093/ecco-jcc/jjv178
  9. Peeters H, Vander Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann Rheum Dis. 2004;63:1131-4. doi: 10.1136/ard.2004.021774
  10. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: Current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002;14:337-41. doi: 10.1097/00002281-200207000-00001
  11. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997;112:1845-53. doi: 10.1053/gast.1997.v112.pm9178675
  12. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002;123:714-8. doi: 10.1053/gast.2002.35396
  13. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585-95. doi: 10.1038/nrgastro.2013.117
  14. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10:43-55. doi: 10.1038/nrg2489
  15. Milia AF, Ibba-Manneschi L, Manetti M, Benelli G, Messerini L, Matucci-Cerinic M. HLA-B27 transgenic rat: An animal model mimicking gut and joint involvement in human spondyloarthritides. Ann NY Acad Sci. 2009;1173:570-4. doi: 10.1111/j.1749-6632.2009.04757.x
  16. Apostolaki M, Manoloukos M, Roulis M, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn’s disease. Gastroenterology. 2008;134:2025-35. doi: 10.1053/j.gastro.2008.02.085
  17. Rahier JF, Buche S, Peyrin-Biroulet L, et al.; Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif [GETAID]. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti- tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-55. doi: 10.1016/j.cgh.2010.07.022
  18. Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: A case series. Ann Rheum Dis. 2017;76:878-81. doi: 10.1136/annrheumdis-2016-210233
  19. Tadbiri S, Peyrin-Biroulet L, Serrero M, et al.; GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: A multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485-93. doi: 10.1111/apt.14419
  20. Hadis U, Wahl B, Schulz O, et al. Intestinal tolerance requires gut hom- ing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity. 2011;34:237-46. doi: 10.1016/j.immuni.2011.01.016
  21. Cassani B, Villablanca EJ, Quintana FJ, et al. Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology. 2011;141:2109-18. doi: 10.1053/j.gastro.2011.09.015
  22. Karreman MC, Luime JJ, Hazes JMW, Weel AEAM. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: A systematic review and meta-analysis. J Crohn’s Colitis. 2017;11:631-42. doi: 10.1093/ecco-jcc/jjw199
  23. Peeters H, Vander Cruyssen B, Mielants H, et al. Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol. 2008;23:132-7. doi: 10.1111/j.1440-1746.2007.05108.x
  24. Bourikas LA, Papadakis KA. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1915-24. doi: 10.1002/ibd.20942
  25. Sepriano A, Rubio R, Ramiro S, Landewé R, van der Heijde D. Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: A systematic literature review and meta-analysis. Ann Rheum Dis. 2017;76:886-90. doi: 10.1136/annrheumdis-2016-210747
  26. Belousova E, Abdulganieva D, Odintsova A, Zakirov R, Nagornykh B, Protopopov M. Performance of ASAS criteria for inflammatory back pain in patients with inflammatory bowel disease. J Crohn’s Colitis. 2017;11 Suppl 1:S160. doi: 10.1093/ecco-jcc/jjx002.289
  27. Van der Heijde D, Lie E, Kvien TK, et al.; Assessment of SpondyloArthritis international Society [ASAS]. ASDAS, a highly discriminatory ASAS – endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811-8. doi: 10.1136/ard.2008.100826
  28. Mease P, Sieper J, van den Bosch F, Rahman P, Karunaratne PM, Pangan AL. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheum. 2015;67:914-23. doi: 10.1002/art.39008
  29. Fornaciari G, Salvarani C, Beltrami M, et al. Muscoloskeletal manifestations in inflammatory bowel disease. Journal Canadien de Gastroenterologie = Canad J Gastroenterol. 2001;15:399-403. doi: 10.1155/ 2001/612531
  30. Palm O, Moum B, Ongre A, et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002;29:511-5.
  31. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387-91. doi: 10.1136/gut.42.3.387
  32. Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:1369-74. doi: 10.1136/ard.2010.145995
  33. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-24. doi: 10.1038/nature11582
  34. El Miedany Y, Youssef S, Ahmed I, et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101:311-7. doi: 10.1111/j.1572-0241.2006.00384.x
  35. Trusko B, Thorne J, Jabs D, et al.; Standardization of Uveitis Nomenclature [SUN] Project. The Standardization of Uveitis Nomenclature [SUN] Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52:259-65, S1-6. doi: 10.3414/ME12-01-0063
  36. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol. 1997;115:61-4. doi: 10.1001/archopht.1997. 01100150063010
  37. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785-96e3. doi: 10.1016/j.ophtha.2013.09.048
  38. Tavarela Veloso F. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20 Suppl 4:50-3. doi: 10.1111/ j.1365-2036.2004.02055.x
  39. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580-5. doi: 10.1136/ pgmj.2004.031633
  40. Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87:281-93. doi: 10.1097/ MD.0b013e318187cc9c
  41. Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Aug;21(8):1982-92. doi: 10.1097/MIB.0000000000000392
  42. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26:265-73. doi: 10.1016/j.clindermatol.2007.10.018
  43. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012-23. doi: 10.1111/j.1572-0241.2006.00504.x
  44. Polcz M, Gu J, Florin T. Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services’ Adult Hospital 1998–2009. J Crohns Colitis. 2011;5:148-51. doi: 10.1016/ j.crohns.2010.10.006
  45. Huang W, McNeely MC. Neutrophilic tissue reactions. Adv Dermatol. 1997;13:33-64.
  46. Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am. 2007;33:787-802, vi. doi: 10.1016/j.rdc.2007.07.016
  47. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn’s disease. Can J Gastroenterol. 2005;19:603-6. doi: 10.1155/2005/323914
  48. Carinanos I, Acosta MB, Domenech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:E153-4. doi: 10.1002/ibd.21723
  49. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo con- trolled trial. Gut. 2006;55:505-9. doi: 10.1136/gut.2005.074815
  50. Cohen PR. Sweet’s syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34. doi: 10.1186/1750-1172-2-34
  51. Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45:202-10. doi: 10.1007/s12016-012-8351-x
  52. Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102:344-50. doi: 10.1111/j.1572-0241.2006.00947.x
  53. Григорьева Г.А., Мешалкин Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011;15:44-9. [Grigoryeva GA, Meshalkin NU. About the problem of systemic manifestations of inflammatory bowel disease. Farmateka. 2011;15:44-9 (In Russ.)].
  54. Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol. 2013;59:571-82. doi: 10.1016/j.jhep.2013.03.015
  55. Thackeray EW, Charatcharoenwitthaya P, Elfaki D, et al. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011;9:52-6. doi: 10.1016/j.cgh.2010.09.020
  56. Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3781-91. doi: 10.3748/ wjg.14.3781
  57. Peyrin-Biroulet L, van Assche G, Gómez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15:25-36.e27. doi: 10.1016/j.cgh.2016.06.025
  58. Cheung KO, Oemar M, Oppe M, Rabin R. EQ-5D User Guide: Basic Information on how to use the EQ-5D Version 2.0. Rotterdam: EuroQoL Group, 2009.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies